Menu
GeneBe

OCLN

occludin, the group of MARVEL domain containing|Tetraspan junctional complex superfamily|Protein phosphatase 1 regulatory subunits

Basic information

Region (hg38): 5:69492291-69558104

Links

ENSG00000197822NCBI:100506658OMIM:602876HGNC:8104Uniprot:Q16625AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • pseudo-TORCH syndrome 1 (Strong), mode of inheritance: AR
  • pseudo-TORCH syndrome 1 (Moderate), mode of inheritance: AR
  • pseudo-TORCH syndrome (Supportive), mode of inheritance: AR
  • pseudo-TORCH syndrome 1 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Pseudo-TORCH syndrome 1 (Band-like calcification with simplified gyration and polymicrogyria)ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic19012351; 19530192; 20727516

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the OCLN gene.

  • not provided (60 variants)
  • Inborn genetic diseases (26 variants)
  • Pseudo-TORCH syndrome 1 (20 variants)
  • not specified (13 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the OCLN gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
6
clinvar
1
clinvar
7
missense
50
clinvar
5
clinvar
1
clinvar
56
nonsense
4
clinvar
2
clinvar
6
start loss
1
clinvar
1
frameshift
2
clinvar
3
clinvar
5
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
1
clinvar
2
clinvar
3
splice region
1
1
2
4
non coding
9
clinvar
6
clinvar
15
Total 7 7 52 21 8

Highest pathogenic variant AF is 0.0000263

Variants in OCLN

This is a list of pathogenic ClinVar variants found in the OCLN region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-69492434-G-A Benign (Sep 17, 2019)1276122
5-69492642-C-T Benign (Apr 18, 2018)378309
5-69492653-G-A not specified Likely benign (Jun 30, 2016)387208
5-69492675-C-G not specified Likely benign (Feb 02, 2018)515390
5-69492986-C-T Benign (Sep 17, 2019)1247058
5-69493132-C-T Benign (Jun 17, 2020)1174443
5-69504175-A-G Uncertain significance (Sep 16, 2018)591558
5-69504248-T-C Pseudo-TORCH syndrome 1 Uncertain significance (Mar 04, 2013)159461
5-69504256-G-C Inborn genetic diseases Uncertain significance (Dec 15, 2022)2335739
5-69504266-AG-A Likely pathogenic (Mar 07, 2018)817656
5-69504278-T-TA Pathogenic (Jan 26, 2024)2711780
5-69504296-T-C Pseudo-TORCH syndrome 1 Likely pathogenic (Oct 19, 2019)1029458
5-69504312-T-C Likely benign (Jun 13, 2022)1654237
5-69508917-T-C Benign (Jun 30, 2018)1240479
5-69508998-T-C Benign (Jun 26, 2018)1264011
5-69509129-T-C Likely benign (Aug 22, 2022)1631125
5-69509133-C-A Likely benign (Aug 15, 2022)1674076
5-69509141-CAAACCGAATCATTATGCACCAAGCAATGACATATATGGTGGAGAGATGCATGTTCGACCAATGCTCTCTCAGCCAGCCTACTCTTTTTACCCAGAAGATGAAATTCTTCACTTCTACAAATGGACCTCTCCTCCAGGAGTGATTCGGATCCTGTCTATGCTCATTATTGTGATGTGCATTGCCATCTTTGCCTGTGTGGCCTCCACGCTTGCCTGGGACAGAGGCTATGGAACTTCCCTTTTAGGAGGTAGTGTAGGCTACCCTTATGGAGGAAGTGGCTTTGGTAGCTACGGAAGTGGCTATGGCTATGGCTATGGTTATGGCTATGGCTACGGAGGCTATACAGACCCAAGAGCAGCAAAGGGCTTCATGTTGGCCATGGCTGCCTTTTGTTTCATTGCCGCGTTGGTGATCTTTGTTACCAGTGTTATAAGATCTGAAATGTCCAGAACAAGAAGATACTACTTAAGTGTGATAATAGTGAGTGCTATCCTGGGCATCATGGTGTTTATTGCCACAATTGTCTATATAATGGGAGTGAACCCAACTGCTCAGTCTTCTGGATCTCTATATGGTTCACAAATATATGCCCTCTGCAACCAATTTTATACACCTGCAGCTACTGGACTCTACGTGGATCAGTATTTGTATCACTACTGTGTTGTGGATCCCCAGGAGGTATGAGTGGTGTTTTGGGTTTTTTCTCCATCTCCTTAGCAGAGGCCTTCAACTTGAGATATGTGATAGAATCACTCTGGAAACTCTTAAAAAATATTGATGACAAGGCTCCACTTCTAATTAAATCTGGGGGAGGGGCTGAGTCTCATTAAGATATGATTAACATACCATGTAATTTGATTACTTAAATAACAGTTCAGTGGTTTTTAATATATTCACAGAATTGTGCCACCATCACCACAATCAATTTTAGAACATTTTCACTATCCTAAAAAGAAACTTGTACCCGTTAGCGGTCACTCCTCATTTCCCTAACCATTCTTAGCCCTAGGCAACCACTAATCCTACATCTATAAATTTGTCTATTCTCTAGGTATTTCATATAAATGGAATCACACAATGTGGTCTTTGTGATGGGCTTCTTTTACGTAGCATAATGTTTTTAAGGTTTACCCATGTCATAGCTTGTGCCATTCTCTCATTCCTTTTTATTGCTAATATTCCAGTGTGTGGATAAACCACATTTTATTTATCAGTTGATAGACATTTGTGTCTACATTGGCTATTAAGAATCATGCTAGACTGGGCACGGTGGCTCATGCTTGTAATCCCAGCACTTTGGGAGGCTGAGGCGGGCGGATCATGAGGTCAGGAGATTGTGACCATCCTCGCTAATAAGGTGAAACCCCGTCTCTACTAAAAATACAAAAAAAATTAGCTGGGCATGGTGGCAGGCACCTGTAGTCCCAGCTACTCGGGAGGCTCAGGCAGAAGAAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCTGAGATTGCGCCACTGCACTCCAGCCTGAGCGACAGAGCAAGACTCCATCTCAAAAAAAAAGAATCATGCTATAGACATTCTTGTATACGTTTTTGTGTGAACCTATGTTTTAATGATTTCTTGAGTTGGGTTATACCTAGGGGTGGAATTGCTGGGTCATATGGTGACTCTTTAATCTTTTGGGGAGCTACCAGAGTTTTTCCAAAGAGTTTGCATCATTTTACATTCACATCAGAAATGTATGAAAGTTCCAATTTCTCCACATCCTCACCAACACTTGTTATTGTCTGATTCTAGCCATGCTGATGGGTGAGAAGTGAAGTGGTGCTTTATTGTGATTTTGATTCGTATTTTCTTTATAGCTAATGTTATTAGCTATATAGTCATGTACTTATTGGCCATTTCTCTCTTATCTTTGGAGAAATGGCTGTTTAGACTTGTCCATTTTTTTTTTCTTTTTGAGACGGAGTCTTGCTCTATCGCCCAGGCTGGAGTGCAGTGGTGTGATCTTTGCTCACTGTGAGCTACGCCTCCTGGGTTCACACCATTCTCCTGCCTCAGCCTCCTGAATAGCTGGGACTACAGGCACCGGCCACCACGCCCAGCTAATTTTTTTTTTTTTTTGTATTTTTAGTAGAGATGGGGTTTCACCGTGTTAGCCACGATGGTCTCTATCTTCTGACCTCGTGATCCGCCCGCCTCGGCCTCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCCGGCCTAGACTTGCCCATGTTTTAATTGGGCTATTTTTGTTGTTGTTTTGTTTTTGAGACAGAGTCTCACTGTCACCCAGGCTGGGGTGCAGTGGTGCAGTCACAGCTCACTGCATCCTTGACCTCCTGGGCTCAAGTGACCCTCCTACCTCAGTCTCCTGAGTAGCTAGGACCACAGGGGCATGCCACCACACCCGGATAATTTTTTAAAAAATTTTTTGTAGAGACAGGGTCTCACTTTGTTGCCCGGTCTGGGCTGGAACTCCTGGGCTCAAGTGATCCTGCCTTGGCCTTCCAAACCGCTGGGATTATAGGCATCTTTTCACTTTCTTGATGGTGTCCTTTGCATAAAAGCTTTTAGTTTTGGGCCGGGCATGGTAGCTCACGCCTGTAATCCCAGCACTTTGGAAGGCCAAGGTGGGCGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACTCCATCTCTACTAAAAATAGAAAAATTACCTGGACACGGTGGCGTGCCTGTAATCCCAGCTACTCAGTAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGTGGAGGTTGCAGTGAGCTGAAATTGTGCCACTGCACTCCAGCCTAGACAACAAGAGCAAAACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAATTTTTAGTTTTGATGATGTCCAGTTTATTTAATTTTTCTTCTGTTGCTTGTATTTTTGGTGTCATATCTAATGCTTTGCCTAATTCAGGGTCACAAGGATTTACTCCTATGTTTTCTATTATTTAATTTTTCTATAGTTTCATAATTTTAGCTTTTACAGTTAGGTCTGTGATTCATGTTGTGTTAATTTTGGGCATGATGGAAGCAAGGGTTCTGAAAGCTTTCGCATGTTTATATGCAGTTGTCTCAGTGTTACTTGTTGAAAGGACTGTTCCTCCACTAAGTTTTCTTCATGCCTTTGTCAAAAATGAATTGATCATAAATGTGGACATTTATTTCTGGGCTCTCAGTTCAGCTGCATTAATCATATGTCCTAATGCCAGTACCATACTGTCTTGATTACTGTAACTTTATAGTAAGTTTTGAAATTGTGGAGTGGGAGTTCTCCAACTTTGTTCTTCAAGACTGTTTTGGCTAGATTCTGGATTCCTTGCATTTCCATATGGATTTTAAGATCAGCATGTCAATTTTGGAAAAAAATGCCAGCTAGGATTTTGAAGGGTTATATTGAATCTGTAGGTCAATTTTGGATGTATTGTCATCTTTACAATTACAAGTCTTCTGATTCATGAACGTAAGATTCTTTTGATTTATGTAGGTCTTGTTAAACTTCTTTTAATAGTGTTTTATAGTTTTCAGAGTGTAAGTTAGTATGTTTAAAAGCTAAGCAAGTGATTCAAATGTGCAGGTTGGAGTTGAGAAACCTACTTTAGTAACCATGAGTCATACTGATTATATTAATATCTGAAATGTTTCTGAGTTACTGATCTTTTTTCCCTTGTTTTTCCTTTTTTCTTACACTAACTCAGGAGTTCCCATTCCTGAATGAGTCACTCCTTTGGAGTTAGACCTCTAGTATCTGTCTACCATTATTTAGAAGACTGAAGGTTTTCCCTGCAGACGTAGGTTTTCACAGTGCTCGTTGTTGCCATTTAGACATGTCCATGGTAGATAGGGACTGAGGGTTGGTACTCCTATCCTACCACACCCCTATCCCTCTTAGTTCTCTTACTACTTACTCTTTGAAAAATGATGTCACTGTCAAGACAGCTGGAAGGAGAGCCTCTTGTTCCCATTAGCAGACATCCAGGGTAGAGGCCTGATATTTCCCTCAACTTCAAGTGCCTCCCAGGCCAATATACCATTTAATATCCTATCACCACTGGGAGAACTGTTAAGAGTAGGAAGTTTCTTTGTTACAGGGCCCTTTCTAGTAGTATGCAAGACTCCTGAAACAGAGAAACCTGCCAGACCAAATCAATCATTAGTCAATTTGCTATTTATAGCTTGATTAGATCCATGTCTTCATCATTTTTGGTAAGATAGAGATCTATGGACAGAAATTTACATTCAGTGTAAAAAGGCTTGCCAAGCATATGTTTTGAACAAGATTACAAGCATGATTGGCTATTTCAAAGCTGTGAATACTTTTGAGAGTAGCATTTTTCAGGCCCTTTAGAAGTATACCAATGATTGAGTTACTTTACTGGCCATTCTCGTAGGTGCACAAAGCTTGGCCCGTAGGTGTACAAGCTTTGGAACTAGTTTTTTACAGCTCTGAAATGAGGGTGATGATTGATAGTTCCTAACATTAGGCATTTTCTGAGGATTGAGTCAAGCAGTATGTACGTGTGTGTACATTTGCTGGCCTTAGCCCAGTTAGTGTGGGTTAGGTTTTATGATATGTCTGAAATGTAACTATTTGCTTCAGTTTTCTATCAATTAAACCACATGGATTTAGTAGGGCCTTAGGGTAGATAAGGGTTTTAATAATATGTAGAGGGTGAATTGTGATTAAGCAATTAAAATCTAATTATGCCAATATTTTCCACTCCTTTTTAGGCCATTGCCATTGTACTGGGGTTCATGATTATTGTGGCTTTTGCTTTAATAATTTTCTTTGCTGTGAAAACTCGAAGAAAGATGGACAGGTATGACAAGTCCAATATTTTGTGGGACAAGGAACACATTTATGATGAGCAGCCCCCCAATGTCGAGGAGTGG-C Pseudo-TORCH syndrome 1 Pathogenic (-)1065616
5-69509147-G-A Likely benign (Dec 31, 2022)2878760
5-69509160-C-G not specified • Pseudo-TORCH syndrome 1 Benign/Likely benign (Mar 01, 2024)159462
5-69509196-C-T Pseudo-TORCH syndrome 1 Pathogenic (Jul 15, 2019)1029457
5-69509211-C-G Inborn genetic diseases Uncertain significance (Jul 08, 2022)1309456
5-69509224-CTT-C Pathogenic (Apr 12, 2022)2125619
5-69509251-A-C Inborn genetic diseases Uncertain significance (Feb 03, 2022)2275724
5-69509259-AAATGGACCTCTCCTCCAGGAGTG-A Pseudo-TORCH syndrome 1 Pathogenic (Sep 10, 2010)6750

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
OCLNprotein_codingprotein_codingENST00000355237 865813
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
8.56e-70.9231256971501257480.000203
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.3222392530.9430.00001283405
Missense in Polyphen8087.4570.914741228
Synonymous2.296390.70.6940.00000510971
Loss of Function1.741321.70.5980.00000116325

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0008720.000872
Ashkenazi Jewish0.0002110.000198
East Asian0.0001090.000109
Finnish0.000.00
European (Non-Finnish)0.0002170.000202
Middle Eastern0.0001090.000109
South Asian0.00009820.0000980
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: May play a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier. It is able to induce adhesion when expressed in cells lacking tight junctions. {ECO:0000269|PubMed:19114660}.;
Disease
DISEASE: Pseudo-TORCH syndrome 1 (PTORCH1) [MIM:251290]: An autosomal recessive neurologic disorder with characteristic clinical and neuroradiologic features that mimic intrauterine TORCH infection in the absence of evidence of infection. Affected individuals have congenital microcephaly, intracranial calcifications, and severe developmental delay. {ECO:0000269|PubMed:20727516}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Cell adhesion molecules (CAMs) - Homo sapiens (human);Tight junction - Homo sapiens (human);Pathogenic Escherichia coli infection - Homo sapiens (human);Hepatitis C - Homo sapiens (human);Leukocyte transendothelial migration - Homo sapiens (human);Pathogenic Escherichia coli infection;VEGFA-VEGFR2 Signaling Pathway;Transcriptional regulation by RUNX1;EMT transition in Colorectal Cancer;Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription;Apoptotic cleavage of cell adhesion proteins;Apoptotic cleavage of cellular proteins;Apoptotic execution phase;Apoptosis;Programmed Cell Death;RUNX1 regulates expression of components of tight junctions;Transcriptional regulation by RUNX1;TGF-beta receptor signaling (Consensus)

Recessive Scores

pRec
0.395

Intolerance Scores

loftool
rvis_EVS
0.48
rvis_percentile_EVS
79.25

Haploinsufficiency Scores

pHI
0.379
hipred
Y
hipred_score
0.733
ghis
0.508

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.932

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Ocln
Phenotype
behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; skeleton phenotype; immune system phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype;

Gene ontology

Biological process
cell-cell junction organization;protein-containing complex assembly;response to interleukin-18;bicellular tight junction assembly;cellular response to tumor necrosis factor;regulation of bicellular tight junction assembly
Cellular component
plasma membrane;cell-cell junction;bicellular tight junction;integral component of membrane;apical plasma membrane;apicolateral plasma membrane;lateral plasma membrane;cell junction;endocytic vesicle;cytoplasmic vesicle
Molecular function
protein binding;protein domain specific binding